T1	intervention 0 10	Carvedilol
T2	condition 38 72	Doxorubicin-Induced Cardiotoxicity
T3	No-of-participants 235 237	70
T4	eligibility 238 315	female patients with breast cancer who were candidates to receive doxorubicin
T5	intervention-participants 342 344	30
T6	control 449 456	placebo
T7	outcome-Measure 567 601	left ventricular ejection fraction
T8	outcome-Measure 606 624	strain/strain rate
T9	outcome 692 738	reduction in strain and strain-rate parameters
T10	outcome 873 910	mean differences of strain parameters
T11	outcome 996 1007	heart walls
T12	outcome 1173 1195	strain-rate parameters
